On September 23, 2022, Alejandro Galindo, the executive vice president endocrine business unit of MannKind Corporation announced that he is resigning from the company, effective at the close of business on October 21, 2022, in order to pursue another opportunity.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.11 USD | +5.14% |
|
+6.46% | +40.38% |
Jun. 22 | MannKind Corporation Announces Positive 17-Week Results from the INHALE-3 Study | CI |
May. 29 | MannKind Agrees to Cross License Deal With Pulmatrix | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+40.38% | 1.39B | |
+15.19% | 121B | |
+19.91% | 114B | |
-19.80% | 20.43B | |
-16.19% | 16.55B | |
-13.45% | 16.45B | |
-44.35% | 15.59B | |
+66.67% | 15.19B | |
+2.13% | 13.54B | |
+119.39% | 10.96B |
- Stock Market
- Equities
- MNKD Stock
- News MannKind Corporation
- Mannkind Corporation Announces Resignation of Alejandro Galindo as Executive Vice President – Endocrine Business Unit, Effective October 21, 2022